Gencurix to acquire GenoPeaks for R&D expansion
젠큐릭스
229000
Signal Score
Historical Avg Return (5d)
+0.00%
Data Coverage
100%n=618
Risk-adjusted indicator based on 618 historical DART filings. For informational purposes only — not investment advice.
Financial Impact
POSITIVE
Key Numbers
- • Gencurix Share Value: 2,389 KRW per share
- • GenoPeaks Share Value: 12,803 KRW per share
- • Merger Ratio (Gencurix:GenoPeaks): 1 : 5.3591461
- • GenoPeaks Total Assets (2025): 203.39M KRW
- • GenoPeaks Net Income (2025): -124.33M KRW
AI Analysis Summary
Gencurix Inc. is proceeding with a small-scale merger to acquire GenoPeaks Co., Ltd. The merger aims to expand Gencurix's business portfolio by integrating GenoPeaks' liquid biopsy analysis expertise and clinical results, enhancing R&D capabilities and market competitiveness. The merger ratio is 1 Gencurix share to 5.3591461 GenoPeaks shares, with Gencurix valued at 2,389 KRW per share and GenoPeaks at 12,803 KRW per share. GenoPeaks reported total assets of 203.39M KRW and a net loss of 124.33M KRW in 2025. The acquisition is expected to strengthen Gencurix's product development and market position without changing its largest shareholder or KOSDAQ listing status. No stock purchase rights are granted to Gencurix shareholders due to the small-scale merger, but shareholders holding 20% or more of shares can object.
Track Korean Market Signals — Free
Sign up free to access live disclosures, AI analysis, and event filters.
Public Beta · No credit card required
This content is for informational purposes only and does not constitute investment advice. Past signal patterns do not guarantee future results. All data is sourced from public DART filings.